{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:13:52Z","timestamp":1790205232240,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["18CDA34110160"],"award-info":[{"award-number":["18CDA34110160"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl. Stroke Res."],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Many neuroprotective and other therapies for treatment of acute ischemic stroke have failed in translation to human studies, indicating a need for more rigorous, multidimensional quality assessment of the totality of preclinical evidence supporting a therapy prior to conducting human trials. A consensus panel of stroke preclinical model and human clinical trial experts assessed candidate items for the translational readiness scale, compiled from prior instruments (STAIR, ARRIVE, CAMARADES, RoB 2) based on importance, reliability, and feasibility. Once constructed, the tool was applied by two independent raters to four current candidate acute stroke therapies, including two pharmacologic agents [nerinetide and trans-sodium crocetinate] and two device interventions [cathodal transcranial direct current stimulation and fastigial nucleus stimulation]. The Preclinical evidence of Readiness In stroke Models Evaluating Drugs and Devices (PRIMED<jats:sup>2<\/jats:sup>) assessment tool rates the totality of evidence available from all reported preclinical animal stroke model studies in 11 domains related to diversity of tested animals, time windows, feasibility of agent route of delivery, and robustness of effect magnitude. Within each content domain, clearly operationalized rules assign strength of evidence ratings of 0\u20132. When applied to the four assessed candidate agents, inter-rater reliability was high (kappa\u2009=\u20090.88), and each agent showed a unique profile of evidentiary strengths and weaknesses. The PRIMED<jats:sup>2<\/jats:sup> assessment tool provides a multidimensional assessment of the cumulative preclinical evidence for a candidate acute stroke therapy on factors judged important for successful basic-to-clinical translation. Further evaluation and refinement of this tool is desirable to improve successful translation of therapies for acute stroke.<\/jats:p>","DOI":"10.1007\/s12975-021-00922-4","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T05:23:51Z","timestamp":1625117031000},"page":"222-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["PRIMED2 Preclinical Evidence Scoring Tool to Assess Readiness for Translation of Neuroprotection Therapies"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-4542","authenticated-orcid":false,"given":"Mersedeh","family":"Bahr-Hosseini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marom","family":"Bikson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Iacoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Liebeskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Hinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Thomas","family":"Carmichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Saver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"922_CR1","doi-asserted-by":"crossref","unstructured":"Nerses Sanossian JLS. Neuroprotection for acute brain ischaemia. In: Hankey JSG, editor. Stroke prevention and treatment: an evidence-based approach. Cambridge University Press; 2020. p. 214\u201338.","DOI":"10.1017\/9781316286234.013"},{"issue":"1","key":"922_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ana.25643","volume":"87","author":"A Schmidt-Pogoda","year":"2020","unstructured":"Schmidt-Pogoda A, Bonberg N, Koecke MHM, Strecker JK, Wellmann J, Bruckmann NM, et al. Why most acute stroke studies are positive in animals but not in patients: a systematic comparison of preclinical, early phase, and phase 3 clinical trials of neuroprotective agents. Ann Neurol. 2020;87(1):40\u201351. https:\/\/doi.org\/10.1002\/ana.25643.","journal-title":"Ann Neurol"},{"issue":"7","key":"922_CR3","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2174\/1570159X18666200114160844","volume":"18","author":"N Dhir","year":"2020","unstructured":"Dhir N, Medhi B, Prakash A, Goyal MK, Modi M, Mohindra S. Pre-clinical to clinical translational failures and current status of clinical trials in stroke therapy: a brief review. Curr Neuropharmacol. 2020;18(7):596\u2013612. https:\/\/doi.org\/10.2174\/1570159X18666200114160844.","journal-title":"Curr Neuropharmacol"},{"key":"922_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clineuro.2014.11.013","volume":"129","author":"S Grupke","year":"2015","unstructured":"Grupke S, Hall J, Dobbs M, Bix GJ, Fraser JF. Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview. Clin Neurol Neurosurg. 2015;129:1\u20139. https:\/\/doi.org\/10.1016\/j.clineuro.2014.11.013.","journal-title":"Clin Neurol Neurosurg."},{"issue":"3","key":"922_CR5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/jcbfm.2010.184","volume":"31","author":"VE O\u2019Collins","year":"2011","unstructured":"O\u2019Collins VE, Macleod MR, Cox SF, Van Raay L, Aleksoska E, Donnan GA, et al. Preclinical drug evaluation for combination therapy in acute stroke using systematic review, meta-analysis, and subsequent experimental testing. J Cereb Blood Flow Metab. 2011;31(3):962\u201375. https:\/\/doi.org\/10.1038\/jcbfm.2010.184.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"922_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s12975-012-0209-2","volume":"4","author":"PA Lapchak","year":"2013","unstructured":"Lapchak PA, Zhang JH, Noble-Haeusslein LJ. RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res. 2013;4(3):279\u201385. https:\/\/doi.org\/10.1007\/s12975-012-0209-2.","journal-title":"Transl Stroke Res"},{"issue":"Suppl 1","key":"922_CR7","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1038\/sj.bjp.0707654","volume":"153","author":"GA Ford","year":"2008","unstructured":"Ford GA. Clinical pharmacological issues in the development of acute stroke therapies. Br J Pharmacol. 2008;153(Suppl 1):S112\u20139. https:\/\/doi.org\/10.1038\/sj.bjp.0707654.","journal-title":"Br J Pharmacol"},{"issue":"3 Suppl","key":"922_CR8","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1161\/STROKEAHA.108.528877","volume":"40","author":"MD Ginsberg","year":"2009","unstructured":"Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke. 2009;40(3 Suppl):S111\u20134. https:\/\/doi.org\/10.1161\/STROKEAHA.108.528877.","journal-title":"Stroke"},{"issue":"3","key":"922_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2165\/00023210-200115030-00001","volume":"15","author":"DS Liebeskind","year":"2001","unstructured":"Liebeskind DS, Kasner SE. Neuroprotection for ischaemic stroke: an unattainable goal? CNS Drugs. 2001;15(3):165\u201374. https:\/\/doi.org\/10.2165\/00023210-200115030-00001.","journal-title":"CNS Drugs"},{"issue":"1","key":"922_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/STROKEAHA.115.011695","volume":"47","author":"J Minnerup","year":"2016","unstructured":"Minnerup J, Zentsch V, Schmidt A, Fisher M, Schabitz WR. Methodological quality of experimental stroke studies published in the Stroke Journal: time trends and effect of the basic science checklist. Stroke. 2016;47(1):267\u201372. https:\/\/doi.org\/10.1161\/STROKEAHA.115.011695.","journal-title":"Stroke"},{"key":"922_CR11","unstructured":"STAIR CONSENSUS CONFERENCE-CYBER STAIR XI. 2020. https:\/\/www.thestair.com\/conference-summary-image. Accessed January 25 2021."},{"key":"922_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.brainres.2009.10.067","volume":"1309","author":"PA Lapchak","year":"2010","unstructured":"Lapchak PA. Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator. Brain Res. 2010;1309:136\u201345. https:\/\/doi.org\/10.1016\/j.brainres.2009.10.067.","journal-title":"Brain Res"},{"issue":"4","key":"922_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3171\/2009.10.JNS09562","volume":"113","author":"H Manabe","year":"2010","unstructured":"Manabe H, Okonkwo DO, Gainer JL, Clarke RH, Lee KS. Protection against focal ischemic injury to the brain by trans-sodium crocetinate Laboratory investigation. J Neurosurg. 2010;113(4):802\u20139. https:\/\/doi.org\/10.3171\/2009.10.JNS09562.","journal-title":"J Neurosurg"},{"key":"922_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.brainres.2014.08.013","volume":"1583","author":"Y Wang","year":"2014","unstructured":"Wang Y, Yoshimura R, Manabe H, Schretter C, Clarke R, Cai Y, et al. Trans-sodium crocetinate improves outcomes in rodent models of occlusive and hemorrhagic stroke. Brain Res. 2014;1583:245\u201354. https:\/\/doi.org\/10.1016\/j.brainres.2014.08.013.","journal-title":"Brain Res"},{"issue":"4","key":"922_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/jnr.23522","volume":"93","author":"J Deng","year":"2015","unstructured":"Deng J, Xiong L, Zuo Z. Trans-sodium crocetinate provides neuroprotection against cerebral ischemia and reperfusion in obese mice. J Neurosci Res. 2015;93(4):615\u201322. https:\/\/doi.org\/10.1002\/jnr.23522.","journal-title":"J Neurosci Res"},{"issue":"5","key":"922_CR16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/aps.2018.5","volume":"39","author":"B Ballarin","year":"2018","unstructured":"Ballarin B, Tymianski M. Discovery and development of NA-1 for the treatment of acute ischemic stroke. Acta Pharmacol Sin. 2018;39(5):661\u20138. https:\/\/doi.org\/10.1038\/aps.2018.5.","journal-title":"Acta Pharmacol Sin"},{"issue":"5594","key":"922_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1126\/science.1072873","volume":"298","author":"M Aarts","year":"2002","unstructured":"Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science. 2002;298(5594):846\u201350. https:\/\/doi.org\/10.1126\/science.1072873.","journal-title":"Science"},{"issue":"7388","key":"922_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nature10841","volume":"483","author":"DJ Cook","year":"2012","unstructured":"Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012;483(7388):213\u20137. https:\/\/doi.org\/10.1038\/nature10841.","journal-title":"Nature"},{"issue":"3","key":"922_CR19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/0271678X15612099","volume":"36","author":"LM Teves","year":"2016","unstructured":"Teves LM, Cui H, Tymianski M. Efficacy of the PSD95 inhibitor Tat-NR2B9c in mice requires dose translation between species. J Cereb Blood Flow Metab. 2016;36(3):555\u201361. https:\/\/doi.org\/10.1177\/0271678X15612099.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"9","key":"922_CR20","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1161\/STROKEAHA.107.506048","volume":"39","author":"HS Sun","year":"2008","unstructured":"Sun HS, Doucette TA, Liu Y, Fang Y, Teves L, Aarts M, et al. Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke. 2008;39(9):2544\u201353. https:\/\/doi.org\/10.1161\/STROKEAHA.107.506048.","journal-title":"Stroke"},{"issue":"6","key":"922_CR21","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/jcbfm.1993.127","volume":"13","author":"F Zhang","year":"1993","unstructured":"Zhang F, Iadecola C. Fastigial stimulation increases ischemic blood flow and reduces brain damage after focal ischemia. J Cereb Blood Flow Metab. 1993;13(6):1013\u20139. https:\/\/doi.org\/10.1038\/jcbfm.1993.127.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"6","key":"922_CR22","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/jcbfm.1993.128","volume":"13","author":"S Yamamoto","year":"1993","unstructured":"Yamamoto S, Golanov EV, Reis DJ. Reductions in focal ischemic infarctions elicited from cerebellar fastigial nucleus do not result from elevations in cerebral blood flow. J Cereb Blood Flow Metab. 1993;13(6):1020\u20134. https:\/\/doi.org\/10.1038\/jcbfm.1993.128.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"922_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0006-8993(97)01017-2","volume":"780","author":"DJ Reis","year":"1998","unstructured":"Reis DJ, Kobylarz K, Yamamoto S, Golanov EV. Brief electrical stimulation of cerebellar fastigial nucleus conditions long-lasting salvage from focal cerebral ischemia: conditioned central neurogenic neuroprotection. Brain Res. 1998;780(1):161\u20135.","journal-title":"Brain Res"},{"issue":"5","key":"922_CR24","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/jcbfm.1991.139","volume":"11","author":"DJ Reis","year":"1991","unstructured":"Reis DJ, Berger SB, Underwood MD, Khayata M. Electrical stimulation of cerebellar fastigial nucleus reduces ischemic infarction elicited by middle cerebral artery occlusion in rat. J Cereb Blood Flow Metab. 1991;11(5):810\u20138. https:\/\/doi.org\/10.1038\/jcbfm.1991.139.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"922_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0006-8993(01)02602-6","volume":"912","author":"SB Glickstein","year":"2001","unstructured":"Glickstein SB, Ilch CP, Reis DJ, Golanov EV. Stimulation of the subthalamic vasodilator area and fastigial nucleus independently protects the brain against focal ischemia. Brain Res. 2001;912(1):47\u201359.","journal-title":"Brain Res"},{"issue":"10","key":"922_CR26","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1523\/JNEUROSCI.19-10-04142.1999","volume":"19","author":"SB Glickstein","year":"1999","unstructured":"Glickstein SB, Golanov EV, Reis DJ. Intrinsic neurons of fastigial nucleus mediate neurogenic neuroprotection against excitotoxic and ischemic neuronal injury in rat. J Neurosci. 1999;19(10):4142\u201354.","journal-title":"J Neurosci"},{"issue":"11","key":"922_CR27","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1161\/STROKEAHA.113.001687","volume":"44","author":"L Peruzzotti-Jametti","year":"2013","unstructured":"Peruzzotti-Jametti L, Cambiaghi M, Bacigaluppi M, Gallizioli M, Gaude E, Mari S, et al. Safety and efficacy of transcranial direct current stimulation in acute experimental ischemic stroke. Stroke. 2013;44(11):3166\u201374. https:\/\/doi.org\/10.1161\/STROKEAHA.113.001687.","journal-title":"Stroke"},{"issue":"1\u20132","key":"922_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jns.2014.05.017","volume":"342","author":"F Notturno","year":"2014","unstructured":"Notturno F, Pace M, Zappasodi F, Cam E, Bassetti CL, Uncini A. Neuroprotective effect of cathodal transcranial direct current stimulation in a rat stroke model. J Neurol Sci. 2014;342(1\u20132):146\u201351. https:\/\/doi.org\/10.1016\/j.jns.2014.05.017.","journal-title":"J Neurol Sci"},{"issue":"10227","key":"922_CR29","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","volume":"395","author":"MD Hill","year":"2020","unstructured":"Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, Demchuk AM, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020;395(10227):878\u201387. https:\/\/doi.org\/10.1016\/S0140-6736(20)30258-0.","journal-title":"Lancet"},{"issue":"6","key":"922_CR30","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1408827","volume":"372","author":"JL Saver","year":"2015","unstructured":"Saver JL, Starkman S, Eckstein M, Stratton SJ, Pratt FD, Hamilton S, et al. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med. 2015;372(6):528\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1408827.","journal-title":"N Engl J Med"},{"key":"922_CR31","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, N.J.: L. Erlbaum Associates; 1988."},{"key":"922_CR32","doi-asserted-by":"publisher","unstructured":"Sch\u00e4fer T, Schwarz MA. The meaningfulness of effect sizes in psychological research: differences between sub-disciplines and the impact of potential biases. Frontiers in Psychology. 2019;10. https:\/\/doi.org\/10.3389\/fpsyg.2019.00813.","DOI":"10.3389\/fpsyg.2019.00813"}],"container-title":["Translational Stroke Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-021-00922-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12975-021-00922-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-021-00922-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T15:59:17Z","timestamp":1647273557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12975-021-00922-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["922"],"URL":"https:\/\/doi.org\/10.1007\/s12975-021-00922-4","relation":{},"ISSN":["1868-4483","1868-601X"],"issn-type":[{"value":"1868-4483","type":"print"},{"value":"1868-601X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"27 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mersedeh Bahr-Hosseini (MBH) receives funding from the American Heart Associaton for developing transcranial direct current stimulation as neuroprotection for treatment of acute cerebral ischemia. MBH has an intellectual property on Transcranial Electrical Stimulation In Stroke Early After Onset.Marom Bikson (MB): The City University of New York holds patents on brain stimulation with MB as inventor. MB has equity in Soterix Medical Inc. MB consults, received grants, assigned inventions, and\/or serves on the SAB of Boston Scientific, GlaxoSmithKline, Biovisics, Mecta, Halo Neuroscience, X. MB is supported by grants from the National Institutes of Health: R01NS101362 (MB), R01NS095123 (MB), R01NS112996 (MB), R01MH111896 (MB), R01MH109289 (MB).Jeffrey L Saver (JLS) receives consulting fees for service on clinical trial design committees from Astrocyte Pharma and Hybernia Medical.All the other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}